Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study

Daquan Wang,1,* Jiayun Chen,1,* Xiaodong Zhang,2 Tao Zhang,1 Luhua Wang,1 Qinfu Feng,1 Zongmei Zhou,1 Jianrong Dai,1 Nan Bi1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Me...

Full description

Bibliographic Details
Main Authors: Wang D, Chen J, Zhang X, Zhang T, Wang L, Feng Q, Zhou Z, Dai J, Bi N
Format: Article
Language:English
Published: Dove Medical Press 2020-10-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/sparing-organs-at-risk-with-simultaneous-integrated-boost-volumetric-m-peer-reviewed-article-CMAR
_version_ 1818342211457122304
author Wang D
Chen J
Zhang X
Zhang T
Wang L
Feng Q
Zhou Z
Dai J
Bi N
author_facet Wang D
Chen J
Zhang X
Zhang T
Wang L
Feng Q
Zhou Z
Dai J
Bi N
author_sort Wang D
collection DOAJ
description Daquan Wang,1,* Jiayun Chen,1,* Xiaodong Zhang,2 Tao Zhang,1 Luhua Wang,1 Qinfu Feng,1 Zongmei Zhou,1 Jianrong Dai,1 Nan Bi1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this workCorrespondence: Nan BiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuannanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 10 87788995Email binan_email@163.comBackground: The technique of simultaneous integrated boost volumetric modulated arc therapy (SIB-VMAT) has been widely used in locally advanced non-small cell lung cancer; however, its dosimetric advantages are seldom reported. This study aimed to quantify dosimetric advantages of SIB-VMAT.Methods: Forty patients with stage III non-small cell lung cancer in our hospital were retrospectively included. SIB-VMAT and conventional VMAT (C-VMAT) plans were generated for every patient using the automatic treatment planning system. A reduced dose was delivered to PTV in SIB-VAMT plans compared to C-VMAT plans (50.4Gy vs 60Gy). The prescribed dose was 50.4 Gy in 28 fractions to PTV and 59.92 Gy in 28 fractions to PGTV in SIB-VMAT plans, while 60 Gy in 30 fractions to PTV in C-VMAT plans. Dose-volume metrics of PTV, total lung, heart, esophagus and spinal cord were recorded. The quality score was used to evaluate organs at risk (OAR) protection for two type prescription plans.Results: Conformal coverage of the targets (PGTV/PTV) by 95% of the prescription dose was well achieved in radiation plans. SIB-VMAT plans achieved significantly higher quality score than C-VMAT plans (Mean: 68.15± 13.32 vs 49.15± 13.35, P< 0.001). More plans scored above sixty in SIB-VMAT group compared to C-VMAT group (72.5% vs 20%, P< 0.001). Notable reductions in mean dose, V30, V40 and V50 of total lung were observed in SIB-VMAT plans compared to C-VMAT plans, with median decreased proportions of 6.5%, 8.7%, 19.6% and 32.1%, respectively. Statistically significant decrease in heart V30 and V40 was also achieved in SIB-VMAT plans, with median decreased proportions of 26.1% and 38.8%. SIB-VMAT plans achieved significant reductions in the maximum doses to both esophagus and spinal cord. Patients with CTV/(GTV+GTVnd) ≥ 8.6 showed more notable decrease in total lung V50 (median, 33.6% vs 28.8%, P=0.001) in SIB-VMAT plans compared to those with the ratio being less than 8.6.Conclusion: SIB-VMAT technique could lead to a substantial sparing of normal organs, including lung, heart, esophagus and cord, mainly through reducing high and inter-median dose exposure. Patients with CTV/(GTV+GTVnd) ≥ 8.6 might benefit more from SIB-VMAT.Keywords: lung cancer, simultaneous integrated boost, radiotherapy, automatic planning, organ at risks
first_indexed 2024-12-13T16:11:05Z
format Article
id doaj.art-1b8dbd71ffc74087bdb57e3083b08bdd
institution Directory Open Access Journal
issn 1179-1322
language English
last_indexed 2024-12-13T16:11:05Z
publishDate 2020-10-01
publisher Dove Medical Press
record_format Article
series Cancer Management and Research
spelling doaj.art-1b8dbd71ffc74087bdb57e3083b08bdd2022-12-21T23:38:56ZengDove Medical PressCancer Management and Research1179-13222020-10-01Volume 129643965357736Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning StudyWang DChen JZhang XZhang TWang LFeng QZhou ZDai JBi NDaquan Wang,1,* Jiayun Chen,1,* Xiaodong Zhang,2 Tao Zhang,1 Luhua Wang,1 Qinfu Feng,1 Zongmei Zhou,1 Jianrong Dai,1 Nan Bi1 1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China; 2Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this workCorrespondence: Nan BiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuannanli, Chaoyang District, Beijing 100021, People’s Republic of ChinaTel +86 10 87788995Email binan_email@163.comBackground: The technique of simultaneous integrated boost volumetric modulated arc therapy (SIB-VMAT) has been widely used in locally advanced non-small cell lung cancer; however, its dosimetric advantages are seldom reported. This study aimed to quantify dosimetric advantages of SIB-VMAT.Methods: Forty patients with stage III non-small cell lung cancer in our hospital were retrospectively included. SIB-VMAT and conventional VMAT (C-VMAT) plans were generated for every patient using the automatic treatment planning system. A reduced dose was delivered to PTV in SIB-VAMT plans compared to C-VMAT plans (50.4Gy vs 60Gy). The prescribed dose was 50.4 Gy in 28 fractions to PTV and 59.92 Gy in 28 fractions to PGTV in SIB-VMAT plans, while 60 Gy in 30 fractions to PTV in C-VMAT plans. Dose-volume metrics of PTV, total lung, heart, esophagus and spinal cord were recorded. The quality score was used to evaluate organs at risk (OAR) protection for two type prescription plans.Results: Conformal coverage of the targets (PGTV/PTV) by 95% of the prescription dose was well achieved in radiation plans. SIB-VMAT plans achieved significantly higher quality score than C-VMAT plans (Mean: 68.15± 13.32 vs 49.15± 13.35, P< 0.001). More plans scored above sixty in SIB-VMAT group compared to C-VMAT group (72.5% vs 20%, P< 0.001). Notable reductions in mean dose, V30, V40 and V50 of total lung were observed in SIB-VMAT plans compared to C-VMAT plans, with median decreased proportions of 6.5%, 8.7%, 19.6% and 32.1%, respectively. Statistically significant decrease in heart V30 and V40 was also achieved in SIB-VMAT plans, with median decreased proportions of 26.1% and 38.8%. SIB-VMAT plans achieved significant reductions in the maximum doses to both esophagus and spinal cord. Patients with CTV/(GTV+GTVnd) ≥ 8.6 showed more notable decrease in total lung V50 (median, 33.6% vs 28.8%, P=0.001) in SIB-VMAT plans compared to those with the ratio being less than 8.6.Conclusion: SIB-VMAT technique could lead to a substantial sparing of normal organs, including lung, heart, esophagus and cord, mainly through reducing high and inter-median dose exposure. Patients with CTV/(GTV+GTVnd) ≥ 8.6 might benefit more from SIB-VMAT.Keywords: lung cancer, simultaneous integrated boost, radiotherapy, automatic planning, organ at riskshttps://www.dovepress.com/sparing-organs-at-risk-with-simultaneous-integrated-boost-volumetric-m-peer-reviewed-article-CMARlung cancersimultaneous integrated boostradiotherapyautomatic planningorgan at risks
spellingShingle Wang D
Chen J
Zhang X
Zhang T
Wang L
Feng Q
Zhou Z
Dai J
Bi N
Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
Cancer Management and Research
lung cancer
simultaneous integrated boost
radiotherapy
automatic planning
organ at risks
title Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
title_full Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
title_fullStr Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
title_full_unstemmed Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
title_short Sparing Organs at Risk with Simultaneous Integrated Boost Volumetric Modulated Arc Therapy for Locally Advanced Non-Small Cell Lung Cancer: An Automatic Treatment Planning Study
title_sort sparing organs at risk with simultaneous integrated boost volumetric modulated arc therapy for locally advanced non small cell lung cancer an automatic treatment planning study
topic lung cancer
simultaneous integrated boost
radiotherapy
automatic planning
organ at risks
url https://www.dovepress.com/sparing-organs-at-risk-with-simultaneous-integrated-boost-volumetric-m-peer-reviewed-article-CMAR
work_keys_str_mv AT wangd sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT chenj sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT zhangx sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT zhangt sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT wangl sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT fengq sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT zhouz sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT daij sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy
AT bin sparingorgansatriskwithsimultaneousintegratedboostvolumetricmodulatedarctherapyforlocallyadvancednonsmallcelllungcanceranautomatictreatmentplanningstudy